Patients & Caregivers

Our commitment to patients and families

At Apogee, we recognize the burden experienced by individuals living with inflammatory and immune diseases. While currently available treatments may have positive effects, they come at a cost for many – with needle fatigue being a significant issue.

We are committed to improving quality of life to people living with these diseases, and are seeking to establish a portfolio of treatments to do just that. Learn more about our scientific approach and ongoing programs:
_{Images do not depict actual patients}

A smiling doctor in a white coat gives a high five to a young girl sitting on a bench in a bright medical facility. The girl holds a stuffed toy, creating a warm and friendly atmosphere that highlights care and trust in the healthcare setting.

A woman in a white tank top gently touches her neck while looking at herself in a mirror. She stands in a bright, plant-filled bathroom, creating a serene and natural atmosphere that highlights self-care and wellness.

A close-up of a baby resting on a parent’s shoulder, looking directly at the camera with curious eyes. The child’s soft expression contrasts with the minimalistic, white background, creating an intimate and tender moment.

A woman in a light pink top stands outdoors with her eyes closed, enjoying the warmth of the sun on her face. The serene setting, surrounded by trees and a clear sky, highlights relaxation and mindfulness in nature.

Patients & Caregivers

Improving validated mechanisms for a potential best-in-class approach

Apogee's antibodies are engineered for best-in-class properties against validated mechanisms. We are bringing forward novel antibodies with improved PK, including longer half-life than currently available options to patients. Utilizing validated binding sites, an optimized backbone, and enhanced manufacturability, we believe we can achieve best-in-class antibodies for our therapeutics indications.

Rethinking treatment of inflammatory and immune diseases

We are passionate in our belief that patients should not have to experience diminished quality of life in order to receive treatment for their inflammatory and immune diseases. That is why we are working swiftly to improve treatment options across a variety of I&I diseases. Our initial target indications include:

Atopic dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by itchy, red skin that can lead to sleep disturbance, psychological distress, elevated infection risk, and chronic pain, all of which significantly impact quality of life. Approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom are living with AD, and 40 percent of these individuals have moderate-to-severe disease. Despite recent advancements in treatment, a significant number of people living with AD continue to suffer from active disease. Today’s treatments are associated with many challenges, including a high frequency of injections that may lead to poor compliance.

Asthma

Asthma is a chronic inflammatory disease in which a person’s airways become inflamed and surrounding muscles tighten. This impact on the airways, coupled with a production of excess mucus, leads to difficulty breathing. More than 27 million people in the United States, or 1 in 12 Americans, have asthma. People living with asthma can experience coughing, shortness of breath, and chest tightening, with symptoms either occurring intermittently or frequently. The difficulty breathing associated with asthma can significantly interfere with an individual’s daily activities and can even lead to life-threatening attacks.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease that is estimated to affect approximately 10% of the global population 40 years of age and older. COPD causes significant, irreversible damage to the lungs over time, and people living with this condition can experience debilitating symptoms such as shortness of breath, chest tightness, coughing, wheezing, and fatigue. While there is no cure for COPD, treatment options are available to slow the progression of disease. That said, despite recent medical advancements in COPD treatment, a significant number of people continue to suffer from the disease.

Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease characterized by abnormal eosinophilic infiltration of the esophagus leading to trouble shallowing, impaction (food stuck in the esophagus), chest pain and regurgitation. Once considered a rare condition, incidence and prevalence rates have rapidly increased with EoE now the most common cause of upper gastrointestinal morbidity. The overall prevalence in the US is approximately 1 in 700, up from 1 in 2,000 in 2014, with more than 400,000 Americans currently suffering from the condition.

Our Clinical Trials

Please see below a list of our current clinical trials.

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Phase 2 Trial of APG777 in adults with moderate-to-severe atopic dermatitis

This study will evaluate the safety and efficacy of APG777 in adult patients with moderate-to-severe atopic dermatitis. Following a 16-week treatment period, two maintenance dose regimens of every 3 months and every 6 months will be evaluated.

Learn more

Phase 1 Trial of APG808 in healthy volunteers and patients with mild-to-moderate asthma

This study will evaluate single ascending doses of APG808 administered subcutaneously in healthy participants and multiple doses in patients with mild-to-moderate asthma.

Phase 1 Trial of APG990 in healthy volunteers

This study will evaluate single ascending doses of APG990 administered subcutaneously in healthy participants.

Phase 1 Trial of APG333 in healthy volunteers

This study will evaluate single ascending doses of APG333 administered subcutaneously in healthy participants.